title: Onychomycosis in Tehran, Iran: prevailing fungi and treatment with itraconazole.
abstract: A total of 187 Patients with suspected onychomycosis were examined for causative fungal agents between 1996 and 1997. Laboratory examination confirmed onychomycosis in 115 patients, of which 97 cases were presented with positive microscopic and cultural examinations, and they were selected for itraconazole pulse therapy. From an etiological point of view, 48.4% of the nail infections, mainly toenail infections, were caused by dermatophytes, 43.3% were infected with Candida spp, specially infected fingernails, and 8.2% by non-dermatophytic molds. Trichophyton mentagrophytes var. interdigital and T. violaceum were the most prevalent species. Candida albicans and C. parapsilosis were the predominant species of the Genus Candida. Scopolariopsis brevicaulis was the most common non-dermatophyte molds observed. Female affected more frequently than male and in both sexes, those who were 30-49 years old, more infected. Toenails were affected more frequently than fingernails. In this study, itraconazole pulse therapy (400 mg daily) gave during the first week of per month for 3 months. The study included 51 patients with toenail onychomychosis (group 1) and 46 patients with fingernail infections (group 2). Patients were followed up for 9 months after the last treatment. Clinical response rates were 83% in the group 1, 95% in the group 2 at month 12; the corresponding mycological cure rates were 71 and 87%, respectively.
authors.affiliation: Department of Medical Mycology, Faculty of Veterinary Medicine, Tehran, Iran. khosravi@chamran.ut.ac.ir
authors.forename: A R
authors.initials: AR
authors.lastname: Khosravi
authors.forename: P
authors.initials: P
authors.lastname: Mansouri
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003883:Arthrodermataceae / Q000302:isolation & purification*; D002175:Candida / Q000302:isolation & purification*; D002648:Child; D003881:Dermatomycoses / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D005533:Foot Dermatoses / Q000188:drug therapy / Q000382:microbiology; D006229:Hand Dermatoses / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D007492:Iran; D017964:Itraconazole / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D014009:Onychomycosis / Q000188:drug therapy / Q000382:microbiology*; D014249:Trichophyton / Q000302:isolation & purification*
chemical_list: D000935:Antifungal Agents; D017964:Itraconazole